We report the case of a patient affected by advanced EGFR mutation-positive lung who experienced resistance to therapy during treatment with Afatinib through the occurrence of a switch of tumor histotype to small cell lung cancer (SCLC) with features of a G3 neuroendocrine carcinoma. Unexpectedly, the switch to SCLC histotype occurred in the only site not responsive to afatinib and subsequently the most responsive to chemotherapy. Our case shows that occurrence of switch to SCLC is a possible mechanism of resistance during treatment with Afatinib.Copyright: Manca et al.
Change from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinib / Manca, P.; Russano, M.; Pantano, F.; Tonini, G.; Santini, D.. - In: ONCOTARGET. - ISSN 1949-2553. - 8:35(2017), pp. 59986-59990. [10.18632/oncotarget.17607]
Change from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinib
Santini D.
2017
Abstract
We report the case of a patient affected by advanced EGFR mutation-positive lung who experienced resistance to therapy during treatment with Afatinib through the occurrence of a switch of tumor histotype to small cell lung cancer (SCLC) with features of a G3 neuroendocrine carcinoma. Unexpectedly, the switch to SCLC histotype occurred in the only site not responsive to afatinib and subsequently the most responsive to chemotherapy. Our case shows that occurrence of switch to SCLC is a possible mechanism of resistance during treatment with Afatinib.Copyright: Manca et al.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
